Coxsackie B: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
(6 intermediate revisions by one other user not shown)
Line 55: Line 55:
*[[Coxsackie B4 virus|Coxsackie B3]] and [[Coxsackie B4 virus|B4]] are related to acute flaccid myelitis.<ref name="pmid28324262">{{cite journal| author=Cho SM, MacDonald S, Frontera JA| title=Coxsackie B3/B4-Related Acute Flaccid Myelitis. | journal=Neurocrit Care | year= 2017 | volume=  | issue=  | pages=  | pmid=28324262 | doi=10.1007/s12028-017-0377-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28324262  }} </ref>
*[[Coxsackie B4 virus|Coxsackie B3]] and [[Coxsackie B4 virus|B4]] are related to acute flaccid myelitis.<ref name="pmid28324262">{{cite journal| author=Cho SM, MacDonald S, Frontera JA| title=Coxsackie B3/B4-Related Acute Flaccid Myelitis. | journal=Neurocrit Care | year= 2017 | volume=  | issue=  | pages=  | pmid=28324262 | doi=10.1007/s12028-017-0377-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28324262  }} </ref>


==Geographic Distribution==  
==Epidemiology and Demographics==  
The various members of the Coxsackie B group were discovered almost entirely in the United States, appearing originally in Connecticut, Ohio, New York, and Kentucky, although a sixth member of the group has been found in the Philippines.<ref name="Fields Virology" />  That said, all six serotypes have a global distribution and are a relatively common cause of gastrointestinal upset.
The various members of the Coxsackie B group were discovered almost entirely in the United States, appearing originally in Connecticut, Ohio, New York, and Kentucky, although a sixth member of the group has been found in the Philippines.<ref name="Fields Virology" />  That said, all six serotypes have a global distribution and are a relatively common cause of gastrointestinal upset.
==Diagnosis==
==Diagnosis==
===History and Symptoms===
===History and Symptoms===
Symptoms of infection with viruses in the Coxsackie B grouping include [[fever]], [[headache]], [[sore throat]], gastrointestinal distress, as well as [[chest pain|chest]] and [[muscle pain]].  This presentation is known as [[pleurodynia]] or Bornholmes disease in many areas. Sufferers of chest pain should see a doctor immediately - in some cases, viruses in the Coxsackie B family progress to myocarditis or pericarditis, which can result in permanent heart damage or death.  Coxsackie B virus infection may also induce [[aseptic meningitis]].  As a group, they are the most common cause of unexpected [[sudden death]], and may account for up to 50% of such cases.<ref>{{cite journal
Symptoms of infection with [[viruses]] in the Coxsackie B grouping include [[fever]], [[headache]], [[sore throat]], gastrointestinal distress, as well as [[chest pain|chest]] and [[muscle pain]].  This presentation is known as [[pleurodynia]] or Bornholmes disease in many areas. Patients with chest pain should see a doctor immediately as it can progress to [[myocarditis]] or [[pericarditis]], which result in permanent heart damage or death.  Coxsackie B virus infection may also induce [[aseptic meningitis]].  As a group, they are the most common cause of unexpected [[sudden death]], and may account for up to 50% of such cases.<ref>{{cite journal
   | last = Maze
   | last = Maze
   | first = S. S.
   | first = S. S.
Line 71: Line 72:
   | date = 1990 Feb
   | date = 1990 Feb
   | accessdate = September 2nd, 2007}}</ref>  The incubation period for the Coxsackie B viruses is, like most of the Enteroviridae, highly variable, ranging from 2 to 35 days, and illness may last for up to two weeks, but may resolve as quickly as two days.  Infection usually occurs between the months of June and October.<ref name="Fields Virology" />
   | accessdate = September 2nd, 2007}}</ref>  The incubation period for the Coxsackie B viruses is, like most of the Enteroviridae, highly variable, ranging from 2 to 35 days, and illness may last for up to two weeks, but may resolve as quickly as two days.  Infection usually occurs between the months of June and October.<ref name="Fields Virology" />
===Laboratory Findings===
===Laboratory Findings===
Enterovirus infection is diagnosed mainly via [[serological]] tests such as [[ELISA]]<ref>{{cite journal
Enterovirus infection is diagnosed mainly via [[serological]] tests such as [[ELISA]]<ref>{{cite journal
Line 83: Line 85:
   | pages = 213-217
   | pages = 213-217
   | date = 1986
   | date = 1986
   | accessdate = September 2nd, 2007}}</ref> and from cell culture.<ref name="Fields Virology" />  Because the same level and type of care is given regardless of type of Coxsackie B infection, it is mostly unnecessary for treatment purposes to diagnose which virus is causing the symptoms in question, though it may be epidemiologically useful.
   | accessdate = September 2nd, 2007}}</ref> and from [[cell culture]].<ref name="Fields Virology" />  Because the same level and type of care is given regardless of type of Coxsackie B infection, it is mostly unnecessary for treatment purposes to diagnose which virus is causing the symptoms in question, though it may be epidemiologically useful.
 
==Treatment==
==Treatment==
===Medical Therapy===
===Medical Therapy===
As of 2007, there is no treatment for the Coxsackie B group of viruses.<ref name="Fields Virology" /> [[Pallative care]] is available, however, and patients suffering chest pain or stiffness of the neck should be examined for signs of cardiac or [[central nervous system]] involvement, respectively.  Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious.  Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced myocarditis or pericarditis, [[antiinflammatory|antiinflammatories]] can be given to reduce damage to the heart muscle. There is no [[vaccine]] for any member of the group.
As of 2007, there is no treatment for the Coxsackie B group of viruses.<ref name="Fields Virology" /> [[Pallative care]] is available, however, and patients suffering chest pain or stiffness of the neck should be examined for signs of cardiac or [[central nervous system]] involvement, respectively.  Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious.  Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced [[myocarditis]] or [[pericarditis]], [[antiinflammatory|antiinflammatories]] can be given to reduce damage to the heart muscle. There is no [[vaccine]] for any member of the group.
 
===Prevention===
===Prevention===
Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious.  Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced myocarditis or pericarditis,[[antiinflammatory|antiinflammatories]] can be given to reduce damage to the heart muscle. There is no [[vaccine]] for any member of the group.
Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious.  Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced [[myocarditis]] or [[pericarditis]],[[antiinflammatory|antiinflammatories]] can be given to reduce damage to the heart muscle. There is no [[vaccine]] for any member of the group.


==References==
==References==
Line 95: Line 99:
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Picornaviruses]]
[[Category:Picornaviruses]]
[[Category:Infectious disease]]
 
[[Category:Disease]]
[[Category:Disease]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]

Latest revision as of 17:29, 18 September 2017

style="background:#Template:Taxobox colour;"|Coxsackie B virus
Coxsackie B4 virus
Coxsackie B4 virus
style="background:#Template:Taxobox colour;" | Virus classification
Group: Group IV ((+)ssRNA)
Family: Picornaviridae
Genus: Enterovirus
Species: Human enterovirus B
Subtype

Coxsackie B virus

WikiDoc Resources for Coxsackie B

Articles

Most recent articles on Coxsackie B

Most cited articles on Coxsackie B

Review articles on Coxsackie B

Articles on Coxsackie B in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Coxsackie B

Images of Coxsackie B

Photos of Coxsackie B

Podcasts & MP3s on Coxsackie B

Videos on Coxsackie B

Evidence Based Medicine

Cochrane Collaboration on Coxsackie B

Bandolier on Coxsackie B

TRIP on Coxsackie B

Clinical Trials

Ongoing Trials on Coxsackie B at Clinical Trials.gov

Trial results on Coxsackie B

Clinical Trials on Coxsackie B at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Coxsackie B

NICE Guidance on Coxsackie B

NHS PRODIGY Guidance

FDA on Coxsackie B

CDC on Coxsackie B

Books

Books on Coxsackie B

News

Coxsackie B in the news

Be alerted to news on Coxsackie B

News trends on Coxsackie B

Commentary

Blogs on Coxsackie B

Definitions

Definitions of Coxsackie B

Patient Resources / Community

Patient resources on Coxsackie B

Discussion groups on Coxsackie B

Patient Handouts on Coxsackie B

Directions to Hospitals Treating Coxsackie B

Risk calculators and risk factors for Coxsackie B

Healthcare Provider Resources

Symptoms of Coxsackie B

Causes & Risk Factors for Coxsackie B

Diagnostic studies for Coxsackie B

Treatment of Coxsackie B

Continuing Medical Education (CME)

CME Programs on Coxsackie B

International

Coxsackie B en Espanol

Coxsackie B en Francais

Business

Coxsackie B in the Marketplace

Patents on Coxsackie B

Experimental / Informatics

List of terms related to Coxsackie B

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

To go back to Coxsackie virus home page, click here.

Overview

Coxsackie B is the name of a group of six serotypes of pathogenic enteroviruses that trigger illness ranging from mild gastrointestinal distress to full-fledged pericarditis, myocarditis, pericardial effusion, pleurodynia and hepatitis.[1]

Viral Structure and Function

Coxsackie B viruses are single-strange positive-sense RNA viruses that are resistant to a wide variety of chemical treatments. The viral particles themselves are roughly 30nm icosahedrons.[2] The virus is most frequently distributed via the fecal-oral route, and infection commonly occurs after eating contaminated food. Coxsackie B viruses are cytolytic, and Coxsackie B2 and B5 viruses have been implicated in hand, foot and mouth disease as well as respiratory infection.[1] Infection in infants is mostly asymptomatic, but sometimes results in the death of the infant, often due to myocarditis.[3] Birth defects may also be present in a coxsackie B infected infant.

Associated Conditions

Epidemiology and Demographics

The various members of the Coxsackie B group were discovered almost entirely in the United States, appearing originally in Connecticut, Ohio, New York, and Kentucky, although a sixth member of the group has been found in the Philippines.[1] That said, all six serotypes have a global distribution and are a relatively common cause of gastrointestinal upset.

Diagnosis

History and Symptoms

Symptoms of infection with viruses in the Coxsackie B grouping include fever, headache, sore throat, gastrointestinal distress, as well as chest and muscle pain. This presentation is known as pleurodynia or Bornholmes disease in many areas. Patients with chest pain should see a doctor immediately as it can progress to myocarditis or pericarditis, which result in permanent heart damage or death. Coxsackie B virus infection may also induce aseptic meningitis. As a group, they are the most common cause of unexpected sudden death, and may account for up to 50% of such cases.[5] The incubation period for the Coxsackie B viruses is, like most of the Enteroviridae, highly variable, ranging from 2 to 35 days, and illness may last for up to two weeks, but may resolve as quickly as two days. Infection usually occurs between the months of June and October.[1]

Laboratory Findings

Enterovirus infection is diagnosed mainly via serological tests such as ELISA[6] and from cell culture.[1] Because the same level and type of care is given regardless of type of Coxsackie B infection, it is mostly unnecessary for treatment purposes to diagnose which virus is causing the symptoms in question, though it may be epidemiologically useful.

Treatment

Medical Therapy

As of 2007, there is no treatment for the Coxsackie B group of viruses.[1] Pallative care is available, however, and patients suffering chest pain or stiffness of the neck should be examined for signs of cardiac or central nervous system involvement, respectively. Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious. Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced myocarditis or pericarditis, antiinflammatories can be given to reduce damage to the heart muscle. There is no vaccine for any member of the group.

Prevention

Some measure of prevention can usually be achieved by basic sanitation on the part of food-service workers, though the viruses are highly contagious. Care should be taken in washing ones hands and in cleaning the body after swimming. In the event of Coxsackie-induced myocarditis or pericarditis,antiinflammatories can be given to reduce damage to the heart muscle. There is no vaccine for any member of the group.

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Fields, Bernard N. (1985). Fields Virology. New York: Raven Press. pp. 739–794. ISBN 0-88167-026-X. Unknown parameter |coauthors= ignored (help)
  2. Libby, Karen (2000). "Coxsackie B virus pathogen card". Retrieved September 2nd, 2007. Check date values in: |accessdate= (help)
  3. Kaplan, M. H. (1983 Nov-Dec). "Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness". Reviews of Infectious Diseases. 5 (6): 1019–1032. Unknown parameter |coauthors= ignored (help); Check date values in: |accessdate=, |date= (help); |access-date= requires |url= (help)
  4. Cho SM, MacDonald S, Frontera JA (2017). "Coxsackie B3/B4-Related Acute Flaccid Myelitis". Neurocrit Care. doi:10.1007/s12028-017-0377-8. PMID 28324262.
  5. Maze, S. S. (1990 Feb). "Myocarditis: unresolved issues in diagnosis and treatment". Clinical Cardiology. 13 (2): 69–79. Unknown parameter |coauthors= ignored (help); Check date values in: |accessdate=, |date= (help); |access-date= requires |url= (help)
  6. Bell, Eleanor J. (1986). "Mu-Antibody capture elisa for the rapid diagnosis of enterovirus infections in patients with aseptic meningitis". Journal of Medical Virology. 19 (3): 213–217. Unknown parameter |coauthors= ignored (help); Check date values in: |accessdate= (help); |access-date= requires |url= (help)

Template:WikiDoc Sources